ABSTRACT
Prenatal alcohol exposure (PAE) can affect brain development in early life, but few studies have investigated the effects of PAE on trajectories of white matter tract maturation in young children. Here we used diffusion weighted imaging (DWI) repeated over three time points in a South African birth cohort, to measure the effects of PAE on patterns of white matter microstructural development during the pre-school years. A total of 342 scans acquired from 237 children as neonates (N=82 scans: 30 PAE; 52 controls) and at ages 2-3 (N=121 scans: 27 PAE; 94 controls) and 6-7 years (N=139 scans: 45 PAE; 94 controls) were included. Maternal alcohol use during pregnancy and other antenatal covariates were collected from 28-32 weeks’ gestation. Linear mixed effects models were implemented to investigate the effects of PAE on fractional anisotropy (FA) and mean diffusivity (MD) in specific white matter tracts over time, while adjusting for child sex and maternal education. We found significant PAE-by-time effects on trajectories of FA development in the left superior cerebellar peduncle (SCP-L: p=0.001; survived FDR correction) and right superior longitudinal fasciculus (SLF-R: p=0.046), suggesting altered white matter development among children with PAE. Compared with controls, children with PAE demonstrated a more rapid change in FA in these tracts from the neonatal period to 2-3 years of age, followed by a more tapered trajectory for the period from 2-3 to 6-7 years of age, with these trajectories differing from unexposed control children. Given their supporting roles in various aspects of neurocognitive functioning (i.e., motor regulation, learning, memory, language), altered patterns of maturation in the SCP and SLF may contribute to a spectrum of physical, social, emotional, and cognitive difficulties often experienced by children with PAE. This study highlights the value of repeated early imaging in longitudinal studies of PAE, and focus for early childhood as a critical window of potential susceptibility as well as an opportunity for early intervention.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the Bill and Melinda Gates Foundation [OPP 1017641], National Institute on Alcohol Abuse and Alcoholism [R21AA023887, R01AA026834-01], US Brain and Behavior Research Foundation [24467], Collaborative Initiative on Fetal Alcohol Spectrum Disorders (CIFASD) [U24 AA014811], South African Medical Research Council, UK Government Newton Fund [NAF002/1001], Wellcome Trust [203525/Z/16/Z], South African National Research Foundation [105865, 120432], ABMRF/The Foundation for Alcohol Research, and Harry Crossley Foundation. The content is solely the responsibility of the authors and does not necessarily represent the official views of the funders.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Human Research Ethics Committee of the University of Cape Town Health Sciences Faculty gave ethical approval for this work (401/2009, 525/2012, 044/2017). The Western Cape Department of Provincial Health Research Ethics Committee gave ethical approval for this work (2011RP45).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
